PLA2G10 and neoplasm: Inhibition of the enzymatic activity of sPLA2-X by varespladib or anti-sPLA2-X antibody allows T cell infiltration into the tumor grafts and sensitizes sPLA2-X-overexpressing tumors to the immunotherapy.